5 Under-the-Radar Biotech Stocks That Could Soar in 2026

The biotech industry is a hotbed of innovation and potential for investors looking for high-risk, high-reward opportunities. While many well-known companies dominate the headlines, there are also hidden gems flying under the radar that could experience substantial growth in 2026.

One such company is Inovio Pharma (INO), valued at $123.8 billion. This clinical-stage biotech firm specializes in using its CELLECTRA delivery technology to develop DNA-based medicines that enable the body to produce its own proteins to combat diseases like HPV, cancer, and infectious diseases. Inovio is set to submit its Biologics License Application (BLA) for INO-3107, a promising candidate for recurrent respiratory papillomatosis (RRP), in the latter half of 2025. With FDA approval and commercial launch expected in 2026, analysts predict a potential upside of 200% from the current stock price.

Terns Pharmaceuticals (TERN), valued at $679.9 billion, is another under-the-radar biopharma company making waves. Focused on developing small-molecule therapies for serious diseases, Terns’ lead candidate, TERN-701, is in a Phase 1 clinical trial for chronic myeloid leukemia (CML) and has shown promising early results. Despite discontinuing development of TERN-601 for obesity, Terns is optimistic about the prospects of TERN-701 and anticipates significant growth potential, with a projected upside of 101% from the current levels.

Cardiol Therapeutics (CRDL), valued at $145.02 million, is a clinical-stage biotech company dedicated to developing anti-inflammatory and anti-fibrotic therapies for heart diseases. Its lead drug candidate, CardiolRx, has shown encouraging results in treating acute myocarditis, positioning it as a potential breakthrough in inflammatory heart disorders. Analysts foresee a potential upside of 602% from the current stock price, reflecting the market’s confidence in Cardiol Therapeutics’ future growth.

Silence Therapeutics (SLN), valued at $344.8 million, is a biotech firm specializing in developing siRNA medicines to target disease-causing genes, particularly in the liver. With promising results from its Phase 1 trial for divesiran, a potential treatment for polycythemia vera (PV), and advancements in its cardiovascular candidate, zerlasiran, Silence Therapeutics is poised for significant growth. Analysts predict a potential upside of 324% from the current stock price, showcasing the market’s bullish sentiment towards the company.

Atara Biotherapeutics (ATRA), valued at $196.7 million, is a biotech company focusing on developing off-the-shelf T-cell immunotherapies for cancer and autoimmune conditions. With the FDA accepting its BLA for Tabelecleucel (tab-cel) for EBV-positive post-transplant lymphoproliferative disorder (PTLD), Atara is on the brink of a major breakthrough. Despite already surpassing its mean target price, analysts believe there is still room for growth, with a potential upside of 96% in the next 12 months.

In conclusion, these under-the-radar biotech stocks offer investors the opportunity to capitalize on potential breakthroughs and significant growth in 2026. With innovative technologies and promising candidates in their pipelines, these companies could be the next big players in the biotech industry.